Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance
Presentations
This is some text inside of a div block.
September 22, 2025
Related announcements
Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer
